EWTX — Edgewise Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics falls after mid-stage study data found insufficient for accelerated approval
Brief: Edgewise Therapeutics Reports Positive Results On Sevasemten Program
Edgewise Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Edgewise Therapeutics Q1 Operating Expenses USD 45.959 Million
U.S. RESEARCH ROUNDUP- Alphabet, Amazon, Meta
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Edgewise falls on safety, efficacy doubts for heart disease drug
Brief: Edgewise Therapeutics Announces Pricing Of $200 Million Underwritten Offering Of Common Stock
Brief: Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy
Brief: Edgewise Therapeutics Q4 Basic EPS USD -0.42
Brief: Edgewise Therapeutics Strengthens Leadership Team
Brief: Edgewise Therapeutics Provides Corporate Update And Highlights Priorities For 2025
U.S. STOCKS ON THE MOVE-Teradyne, Keysight Technologies, Ametek
U.S. STOCKS ON THE MOVE-HeartBeam, Teradyne, Keysight Technologies
U.S. STOCKS ON THE MOVE-Novo Nordisk, Tesla, MicroStrategy
U.S. STOCKS ON THE MOVE-NetApp, Honeywell, CBRE Group
Edgewise Therapeutics gains as genetic disorder drug meets mid-stage study goal